Javascript must be enabled to continue!
A summary of drugs targeting enzymes
View through CrossRef
Enzymes act as biological catalysts in living organisms, by regulating the rate of chemical reactions, without themselves being altered in the process. Enzymes act as a target for drugs for the desired therapeutic effect, which are thereby called biological targets. Enzymes offer unique opportunities for drug design that are not available to cell surface receptors, nuclear hormone receptors, ion channels, transporters. Drugs that function as enzyme inhibitors constitute a significant portion of the orally bioavailable therapeutic agents that are in clinical use today. Likewise, much of drug discovery and development efforts at present are focused on identifying and optimizing drug candidates that act through inhibition of specific enzyme targets. Drugs acting on enzymes can either inhibit them or activate them. Inhibition of enzymes is a strategy which is more commonly used rather than activation of enzymes. 47% of all current drugs inhibit their enzyme targets. Enzyme activity can not only be inhibited; it can also be accelerated through biochemical modification of the enzyme. In this manuscript, the authors provide a system-wise summary of drugs acting on enzymes, microsomal enzymes targeted by drug and newly approved drugs acting on enzymes.
Title: A summary of drugs targeting enzymes
Description:
Enzymes act as biological catalysts in living organisms, by regulating the rate of chemical reactions, without themselves being altered in the process.
Enzymes act as a target for drugs for the desired therapeutic effect, which are thereby called biological targets.
Enzymes offer unique opportunities for drug design that are not available to cell surface receptors, nuclear hormone receptors, ion channels, transporters.
Drugs that function as enzyme inhibitors constitute a significant portion of the orally bioavailable therapeutic agents that are in clinical use today.
Likewise, much of drug discovery and development efforts at present are focused on identifying and optimizing drug candidates that act through inhibition of specific enzyme targets.
Drugs acting on enzymes can either inhibit them or activate them.
Inhibition of enzymes is a strategy which is more commonly used rather than activation of enzymes.
47% of all current drugs inhibit their enzyme targets.
Enzyme activity can not only be inhibited; it can also be accelerated through biochemical modification of the enzyme.
In this manuscript, the authors provide a system-wise summary of drugs acting on enzymes, microsomal enzymes targeted by drug and newly approved drugs acting on enzymes.
Related Results
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
This review summarizes the evidence from six randomized controlled trials that judged the effectiveness of systematic review summaries on policymakers' decision making, or the most...
Enzyme Activity: Allosteric Regulation
Enzyme Activity: Allosteric Regulation
Abstract
Cells can respond to changes in their environment by altering the flow through special, regulated metabolic steps perfor...
Three in One: Systemic Lupus Erythematosus, HELLP Syndrome, and Antiphospholipid Syndrome: A Case Report and Literature Review
Three in One: Systemic Lupus Erythematosus, HELLP Syndrome, and Antiphospholipid Syndrome: A Case Report and Literature Review
Abstract
Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease commonly affecting women of reproductive age. Its overlap with HELLP syndrome (Hemolysi...
Recent advances in the pharmacotherapy of osteoarthritis
Recent advances in the pharmacotherapy of osteoarthritis
Introduction: Osteoarthritis (OA) is a common debilitating disease affecting the geriatric population. Management of osteoarthritis is a challenge for orthopedicians because till d...
Health policies and programs facilitating access to high-cost anticancer drugs
Health policies and programs facilitating access to high-cost anticancer drugs
Access to anticancer drugs is limited mainly due to their high cost. To support policymakers in Thailand to develop policies and programs to facilitate better access to high-cost a...
Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs
Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs
ObjectiveOrphan oncology drugs used in this article were defined by the type of disease treated by drugs, as drugs used to treat rare diseases with a prevalence of ≤ 500 per millio...
COST-EFFECTIVENESS OF ORPHAN DRUGS FOR LEUKEMIA TREATMENT: A SYSTEMATIC REVIEW
COST-EFFECTIVENESS OF ORPHAN DRUGS FOR LEUKEMIA TREATMENT: A SYSTEMATIC REVIEW
Introduction: Leukemia is a rare disease related to hematologic cancer stemming from the bone marrow. The Vietnam Ministry of Health (MOH) promulgated the Orphan Drugs List, in whi...
Application of Enzymes in Biomass Waste Management
Application of Enzymes in Biomass Waste Management
Enzymes are biological molecules produced by living entities for carrying out biological processes. The application of enzymes for waste treatment has been gaining pace commerciall...

